SGLT-2 Therapy Center

The use of SGLT2 inhibitors was associated with reduced risk of any cause of death in patients with or without a history of major cardiovascular disease.

Examining both the clinical and the cost outcomes for patients with type 2 diabetes with established cardiovascular disease.

Could a newer diabetes medication provided clinicians with an alternative when managing heart failure?

The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.

While rare, Fournier gangrene infections can worsen rapidly and have serious consequences. 

The use of SGLT-2 inhibitors produces cardiovascular benefits and reduces the risk of progression of renal impairment in patients with T2DM. 

While the major impact of hypomagnesemia on cardiovascular outcomes and T2DM has been known, recent evidence suggests that SGLT2 inhibitors may normalize Mg2+ levels.  

Kidney failure is an enormous concern for people with T2D and DKD. This analysis confirms canagliflozin can slow its progression and have an impact on patients regardless of their level of kidney function.

The first oral glucagon-like peptide receptor agonist recently gained FDA approval, but how does it compare to oral agents already on the market?

Did the FDA make a mistake by labeling SGLT2 inhibitors as a fracture risk?